Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 10/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458354 | 0.81 | CCR5 (0.56) | MMP1MMP3MMP9CCR5GLA | |
| SCHEMBL4458416 | 0.76 | CCR5 (0.67) | MMP1MMP3MMP9CCR5 | |
| SCHEMBL4461057 | 0.71 | CCR5 (0.58) | CCR5 | |
| SCHEMBL4461624 | 0.71 | GRM2 (0.44) | CCR5 | |
| SCHEMBL4461636 | 0.70 | GRM2 (0.36) | CCR5 | |
| SCHEMBL4473543 | 0.68 | CCR5 (0.44) | MMP1MMP3MMP9CCR5GLA | |
| SCHEMBL4473550 | 0.67 | CCR5 (0.44) | MMP1MMP3MMP9CCR5GLA | |
| SCHEMBL13864794 | 0.67 | CCR5 (0.66) | MMP1MMP3MMP9CCR5 | |
| SCHEMBL30623501 | 0.63 | GRM2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL3228128 | 0.62 | GRM2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| US-20050176703-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | MMP1 4411/4885MMP3 3794/4885MMP9 4180/4885 |
| US-20050176703-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | MMP1 4411/4885MMP3 3794/4885MMP9 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.